Brought to you by 
Biogen Idec gets global rights to Knopp's ALS candidate; Deal terminated
06 May 2020
Executive Summary
Knopp Neurosciences Inc. has licensed Biogen Idec Inc. exclusive worldwide rights to develop and commercialize Phase II KNS760704 (dexpramipexole) for amyotrophic lateral sclerosis and other indications.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Equity
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Biogen Idec gets global rights to Knopp's ALS candidate; Deal terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice